tobramycin
treatment
infections
due
pseudomonas
aeruginosa
patients
cystic
fibrosis
effectiveness
safety
tobramycin
infections
due
pseudomonas
aeruginosa
patients
cystic
fibrosis
studied
patients
moderate
severe
exacerbation
chronic
pulmonary
infection
seventeen
courses
treatment
given
tobramycin
mg
kg
per
day
administered
intravenously
three
divided
doses
per
day
seven
days
specimens
sputum
yielded
moderate
heavy
growth
p
aeruginosa
isolates
inhibited
mug
tobramycin
ml
seven
cases
isolates
inhibited
mug
gentamicin
ml
mean
levels
tobramycin
blood
mug
ml
hr
mug
ml
hr
administration
patients
received
antistaphylococcal
agent
therapy
patients
except
two
received
mg
carbenicillin
kg
per
day
intravenously
six
divided
doses
g
carbenicillin
mask
inhalation
three
times
day
clinical
radiological
improvement
noted
patients
white
blood
cell
count
elevated
seven
patients
returned
normal
levels
blood
gases
improved
p
aeruginosa
eliminated
sputum
five
cases
adverse
side
effects
noted
